CELLTRION

CELLTRION

approved_indications FDA Approved Biologics and Pending Applications

CT-P39

omalizumab
CT-P39 Approval Pending

CT-P41

denosumab
CT-P41 Approval Pending

CT-P42

aflibercept
CT-P42 Approval Pending

CT-P43

ustekinumab
CT-P43 Approval Pending

CT-P47

tocilizumab
CT-P47 Approval Pending

Herzuma®

trastuzumab-pkrb
aBL 761091

Inflectra®

Infliximab-dyyb
aBL 125544

Truxima®

rituximab-abbs
aBL 761088

Vegzelma®

bevacizumab-adcd
aBL 761268

Yuflyma®

adalimumab-aaty
aBL 761219

Zymfentra

Infliximab-dyyb (for subcutanous use)
BL 761358

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Herzuma® (trastuzumab) (Celltrion / Teva) (September-2019)Remsima (infliximab) (Celltrion) (January-2014) Remsima SC (subcutaneous infliximab) (Celltrion) (February-2021)Truxima® (rituximab) (Teva) (April-2019)Vegzelma® (bevacizumab) (Celltrion) (January-2023)Yuflyma® (high-concentration adalimumab) (Celltrion) (December-2021)

Biosimilars Approved In The E.U.

Blitzima (rituximab) (Celltrion) (July-2017) Herzuma® (trastuzumab) (Celltrion) (February-2018)Remsima (infliximab) (Celltrion) (September-2013) Remsima SC (subcutaneous infliximab) (Celltrion) (November-2019)Ritemvia (rituximab) (Celltrion (July-2017) Rituzena (rituximab) (Celltrion) (July-2017)Truxima® (rituximab) (Celltrion) (February-2017) Vegzelma® (bevacizumab) (Celltrion) (August-2022, UK: September-2022)Yuflyma® (high-concentration adalimumab) (Celltrion) (February-2022)Yuflyma® (low-concentration adalimumab) (Celltrion) (February-2021)

Biosimilars Approved In Australia

Herzuma® (trastuzumab) (Celltrion) (August-2018)Truxima® (rituximab) (Celltrion) (April-2018)Vegzelma® (bevacizumab) (Celltrion) (September-2023)

Biosimilars Approved In Japan

CT-P6 (trastuzumab) (Celltrion / Nippon Kayaku) (August-2018)Infliximab BS (infliximab) (Remsima) (Celltrion / Nippon Kayaku) (July-2014)Vegzelma® (bevacizumab) (Celltrion) (September-2022)

Biosimilars Approved In South Korea

Herzuma® (trastuzumab) (Celltrion) (January-2014)Remsima (infliximab) (Celltrion) (July-2012) Truxima® (CT P10) (rituximab) (Celltrion) (November-2016)Vegzelma® (bevacizumab) (Celltrion) (September-2022)Yuflyma® (high-concentration adalimumab) (Celltrion) (October-2021)

approved_indications Inter Partes Review Proceedings

ACTEMRA / CT-P47IPR2022-00578
IPR2022-00579
EYLEA / CT-P42IPR2022-00257
IPR2022-00258
IPR2023-00462
IPR2023-00532
IPR2023-00533
IPR2023-00620
IPR2024-00260
PGR2021-00117
HERCEPTIN / HERZUMAIPR2017-00959
IPR2017-01121
IPR2017-01122
IPR2017-01139
IPR2017-01140
IPR2017-01373
IPR2017-01374
RITUXAN / TRUXIMAIPR2015-01733
IPR2015-01744
IPR2016-01614
IPR2016-01667
IPR2017-01093
IPR2017-01094
IPR2017-01095
IPR2017-01227
IPR2017-01229
IPR2017-01230
IPR2018-01019

approved_indications U.S. Patent Litigations

EYLEA / CT-P421:23-cv-00089 (N.D.W. Va.)
HERCEPTIN / HERZUMA / GENENTECH CABILLY1:18-cv-00095 (D. Del.)
1:18-cv-01025 (D. Del.)
4:18-cv-00274 (N.D. Cal.)
REMICADE / INFLECTRA1:14-cv-02256 (S.D.N.Y.)
1:14-cv-11613 (D. Mass.)
1:15-cv-10698 (D. Mass.)
1:16-cv-11117 (D. Mass.)
1:17-cv-11008 (D. Mass.)
RITUXAN / TRUXIMA / GENENTECH CABILLY1:18-cv-00574 (D.N.J.)
1:18-cv-11553 (D.N.J.)
4:18-cv-00276 (N.D. Cal.)

Related News

EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed for Lack of Jurisdiction
Robert S. Schwartz, Ph.D.
April 17, 2024
Genentech and Dr. Reddy’s Settle BPCIA Litigation Against Proposed Rituxan Biosimilar DRL_RI
Robert S. Schwartz, Ph.D.
April 15, 2024
Venable’s BiologicsHQ Monthly Injection – March 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
April 10, 2024
Celltrion Submits aBLA for CT-P39, Proposed Interchangeable Biosimilar of Xolair® (omalizumab)
Monica Chou Robert S. Schwartz, Ph.D.
March 31, 2024
Spotlight On: Actemra® (tocilizumab) / Tofidence™ (tocilizumab-bavi) / Tyenne® (tocilizumab-aazg)
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
March 31, 2024
Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb) / Trazimera® (trastuzumab-qyyp) / Kanjinti® (trastuzumab-anns)
April Breyer Menon Frederick C. Millett Corinne E. Atton Robert S. Schwartz, Ph.D.
March 31, 2024
Spotlight On: Biosimilar Litigations
April Breyer Menon Ha Kung Wong
March 31, 2024
Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)
April Breyer Menon Corinne E. Atton Joyce L. Nadipuram Robert S. Schwartz, Ph.D.
March 31, 2024
EYLEA® IPR Appeals Filed
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
March 21, 2024
The First Prolia® / Xgeva® Biosimilar Approvals in the U.S.
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
March 15, 2024
Venable’s BiologicsHQ Monthly Injection – February 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
March 13, 2024
Fresenius Kabi’s Actemra® biosimilar Tyenne® (tocilizumab-aazg) Approved in the U.S.
Robert S. Schwartz, Ph.D.
March 12, 2024
Stelara® Biosimilar Updates: Settlement of IPR and FDA Review of Proposed Biosimilar
Monica Chou Robert S. Schwartz, Ph.D.
March 6, 2024
Chugai, Genentech, and Hoffmann-La Roche Dismiss Appeals of Actemra® Patent IPR Final Written Decisions
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
February 20, 2024
Venable’s BiologicsHQ Monthly Injection – January 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
February 13, 2024
The PTAB Finds Claims of Two EYLEA® Patents Unpatentable and Regeneron Files its Sixth Complaint Against a Proposed EYLEA® Biosimilar
Damineh Morsali, Ph.D. Robert S. Schwartz
January 31, 2024
Celltrion Submits an aBLA for Actemra® (tocilizumab) Proposed Biosimilar CT-P47
Robert S. Schwartz
January 31, 2024
Venable’s BiologicsHQ Monthly Injection – December 2023
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
January 13, 2024
EYLEA® (aflibercept) and Soliris® (eculizumab) IPR and BPCIA Litigation Updates
Robert S. Schwartz Monica Chou Damineh Morsali, Ph.D.
December 31, 2023
Celltrion Completes Application for FDA Approval of CT-P41, Biosimilar of Prolia® / Xgeva®
Monica Chou Robert S. Schwartz
December 19, 2023
EYLEA® (aflibercept) IPR and BPCIA Litigation Updates
Damineh Morsali, Ph.D. Robert S. Schwartz
December 15, 2023
BPCIA Complaint Against Proposed Rituxan® Biosimilar DRL_RI Filed
Monica Chou Robert S. Schwartz, Ph.D.
December 13, 2023
Stelara® Biosimilar Updates: IPR Petition Challenging U.S. Patent No. 10,961,307 Filed and SB17 Settlement and Launch Date Announced
Monica Chou Robert S. Schwartz, Ph.D.
December 8, 2023
BPCIA Litigation Related to Proposed Eylea Biosimilar CT-P42 Filed
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
November 22, 2023
First Biosimilar and Interchangeable of Stelara® (ustekinumab) Approved in the U.S.
Robert S. Schwartz, Ph.D.
November 5, 2023
Venable’s BiologicsHQ Monthly Injection – September 2023
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
October 16, 2023
Venable’s BiologicsHQ Monthly Injection – August 2023
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 12, 2023
Venable’s BiologicsHQ Monthly Injection – July 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 15, 2023
What Do the Humira Biosimilar / Interchangeable Launches Mean for the Adalimumab Market?
April Breyer Menon Ha Kung Wong
August 7, 2023
Venable’s BiologicsHQ Monthly Injection – June 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 15, 2023
Venable’s BiologicsHQ Monthly Injection – May 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 13, 2023
Venable’s BiologicsHQ Monthly Injection – April 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
May 8, 2023
Venable’s BiologicsHQ Monthly Injection – March 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 10, 2023
Venable’s BiologicsHQ Monthly Injection – February 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 15, 2023
Venable’s BiologicsHQ Monthly Injection – January 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
February 9, 2023
First Humira Biosimilar Enters the U.S. Market
April Breyer Menon Ha Kung Wong
February 3, 2023
Venable’s BiologicsHQ Monthly Injection – December 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
January 12, 2023
Venable’s BiologicsHQ Monthly Injection – November 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
December 14, 2022
Venable’s BiologicsHQ Monthly Injection – September 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
October 11, 2022
Venable’s BiologicsHQ Monthly Injection – August 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 8, 2022
Venable’s BiologicsHQ Monthly Injection – February 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 8, 2022
Venable’s BiologicsHQ Monthly Injection – October 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
November 10, 2021
Venable’s BiologicsHQ Monthly Injection – September 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
October 12, 2021
Venable’s BiologicsHQ Monthly Injection – February 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 9, 2021
Venable’s BiologicsHQ Monthly Injection – August 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 9, 2020
Venable’s BiologicsHQ Monthly Injection – June 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 9, 2020
Venable’s BiologicsHQ Monthly Injection – March 2020
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
April 8, 2020
Venable’s BiologicsHQ Monthly Injection – November 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
December 9, 2019
Venable’s BiologicsHQ Monthly Injection – September 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
October 8, 2019
Venable’s BiologicsHQ Monthly Injection – March 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
April 5, 2019
Venable’s BiologicsHQ Monthly Injection – December 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
January 9, 2019
Venable’s BiologicsHQ Monthly Injection – November 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
December 11, 2018
Venable’s BiologicsHQ Monthly Injection – October 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
November 12, 2018
Venable’s BiologicsHQ Monthly Injection – August 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
September 6, 2018
Venable’s BiologicsHQ Monthly Injection – July 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
August 3, 2018
Venable’s BiologicsHQ Monthly Injection – June 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
July 6, 2018
Venable’s BiologicsHQ Monthly Injection – April 2018
April M. Breyer Menon Corinne E. Atton Joseph K. Yarsky Robert S. Schwartz, Ph.D.
May 3, 2018
Venable’s BiologicsHQ Monthly Injection – December 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
January 8, 2018
VIDEO: How Important is Inter Partes Review to Biosimilars?
Ha Kung Wong
August 9, 2017
Venable’s BiologicsHQ Monthly Injection – July 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
July 26, 2017
The U.S. Biosimilars Market is Heating Up: Guidance from the Federal Circuit is Expected Late Spring
Robert S. Schwartz, Ph.D. Corinne E. Atton
April 6, 2015
The FDA Approves Zarxio® Opening the Door to the U.S. Biosimilars Market
Robert S. Schwartz, Ph.D. Corinne E. Atton
March 6, 2015

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha